Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary W Redman

Showing results (61-70 of 86) with videos related to

Pageof 9
Sort By:
Cancer|December 8, 2016
Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation studyKelly G Paulson, Christopher W Lewis, Mary W Redman, et al.
Clinical Lung Cancer|November 22, 2020
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)Saiama N Waqar, Mary W Redman, Susanne M Arnold, et al.
Clinical Lung Cancer|March 22, 2021
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811)Athanassios Argiris, Jieling Miao, Mihaela C Cristea, et al.
JCO Oncology Practice|April 2, 2021
Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN)Joshua A Roth, Meghna S Trivedi, Stacy W Gray, et al.
Blood|September 8, 2020
A prospective, blinded study of a PF4-dependent assay for HIT diagnosisBethany Samuelson Bannow, Deepti M Warad, Curtis G Jones, et al.
JCI Insight|December 20, 2019
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLCJulia Kargl, Xiaodong Zhu, Huajia Zhang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapiesAlan P Venook, Maria E Arcila, Al B Benson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012Herbert H Pang, Xiaofei Wang, Thomas E Stinchcombe, et al.
Journal for Immunotherapy of Cancer|August 25, 2021
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)Natasha B Leighl, Mary W Redman, Naiyer Rizvi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 9, 2023
Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent AdenomasMing Yu, Kelly T Carter, Kelsey K Baker, et al.
Pageof 9

Showing results (61-70 of 86) with videos related to

Sort By:
Pageof 9
Cancer|December 8, 2016
Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation studyKelly G Paulson, Christopher W Lewis, Mary W Redman, et al.
Clinical Lung Cancer|November 22, 2020
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)Saiama N Waqar, Mary W Redman, Susanne M Arnold, et al.
Clinical Lung Cancer|March 22, 2021
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811)Athanassios Argiris, Jieling Miao, Mihaela C Cristea, et al.
JCO Oncology Practice|April 2, 2021
Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN)Joshua A Roth, Meghna S Trivedi, Stacy W Gray, et al.
Blood|September 8, 2020
A prospective, blinded study of a PF4-dependent assay for HIT diagnosisBethany Samuelson Bannow, Deepti M Warad, Curtis G Jones, et al.
JCI Insight|December 20, 2019
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLCJulia Kargl, Xiaodong Zhu, Huajia Zhang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapiesAlan P Venook, Maria E Arcila, Al B Benson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012Herbert H Pang, Xiaofei Wang, Thomas E Stinchcombe, et al.
Journal for Immunotherapy of Cancer|August 25, 2021
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)Natasha B Leighl, Mary W Redman, Naiyer Rizvi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 9, 2023
Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent AdenomasMing Yu, Kelly T Carter, Kelsey K Baker, et al.
Pageof 9